Roivant Sciences (ROIVW) Stock News, Jun-Sep 2023

ROIVW Nasdaq

09/11/2023 08:00 AM

News

Roivant Announces Completion of Redemption of its Outstanding Warrants

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

08/17/2023 04:05 PM

News

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.45%

Tags

-

08/14/2023 07:00 AM

News

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.7%

Tags

08/03/2023 04:05 PM

News

Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.73%

Tags

-

08/02/2023 04:05 PM

News

Roivant Announces Redemption of Outstanding Warrants

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-9.69%

Tags

-

07/27/2023 08:00 AM

News

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.54%

Tags

06/28/2023 07:00 AM

News

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

17.39%

Tags

-

06/26/2023 04:05 PM

News

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.91%

Tags

-

06/22/2023 07:30 AM

News

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.41%

Tags

06/21/2023 05:00 PM

News

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.41%

Tags